Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Individual bioenergetic capacity as a potential source of resilience to Alzheimer’s disease

View ORCID ProfileMatthias Arnold, Mustafa Buyukozkan, P. Murali Doraiswamy, Kwangsik Nho, Tong Wu, Vilmundur Gudnason, Lenore J. Launer, Rui Wang-Sattler, Jerzy Adamski, The Alzheimer’s Disease Neuroimaging Initiative, Alzheimer’s Disease Metabolomics Consortium, View ORCID ProfilePhilip L. De Jager, Nilüfer Ertekin-Taner, David A. Bennett, View ORCID ProfileAndrew J. Saykin, View ORCID ProfileAnnette Peters, View ORCID ProfileKarsten Suhre, Rima Kaddurah-Daouk, View ORCID ProfileGabi Kastenmüller, View ORCID ProfileJan Krumsiek
doi: https://doi.org/10.1101/2024.01.23.23297820
Matthias Arnold
1Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, USA
2Institute of Computational Biology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Matthias Arnold
  • For correspondence: matthias.arnold{at}helmholtz-muenchen.de jak2043{at}med.cornell.edu
Mustafa Buyukozkan
3Institute for Computational Biomedicine, Englander Institute for Precision Medicine, Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. Murali Doraiswamy
1Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, USA
4Duke Institute of Brain Sciences, Duke University, Durham, NC, USA
5Department of Medicine, Duke University, Durham, NC, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kwangsik Nho
6Department of Radiology and Imaging Sciences and Indiana Alzheimer’s Disease Research Center, Indiana University School of Medicine, Indianapolis, IN, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tong Wu
2Institute of Computational Biology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vilmundur Gudnason
7Faculty of Medicine, University of Iceland, Reykjavik, Iceland
8Icelandic Heart Association, Kopavogur, Iceland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lenore J. Launer
9Laboratory of Epidemiology and Population Science, National Institute on Aging, Bethesda, Maryland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rui Wang-Sattler
10Research Unit of Molecular Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jerzy Adamski
11Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany
12Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
13Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philip L. De Jager
14Center for Translational & Computational Neuroimmunology, Department of Neurology, Taub Institute, Columbia University Irving Medical Center, New York Presbyterian Hospital, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Philip L. De Jager
Nilüfer Ertekin-Taner
15Departments of Neuroscience and Neurology, Mayo Clinic, Jacksonville, FL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David A. Bennett
16Rush Alzheimer’s Disease Center, Rush University Medical Center, Chicago, IL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew J. Saykin
6Department of Radiology and Imaging Sciences and Indiana Alzheimer’s Disease Research Center, Indiana University School of Medicine, Indianapolis, IN, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Andrew J. Saykin
Annette Peters
17Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany; IBE, Medical Faculty, Ludwig-Maximilians-Universität, Munich, Germany; German Center for Diabetes Research (DZD e.V.), Munich, Germany; German Center for Cardiovascular Disease (DZHK e.V.), Munich Heart Alliance, Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Annette Peters
Karsten Suhre
18Department of Physiology and Biophysics, Weill Cornell Medicine-Qatar, Education City, Doha, Qatar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Karsten Suhre
Rima Kaddurah-Daouk
1Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, USA
4Duke Institute of Brain Sciences, Duke University, Durham, NC, USA
5Department of Medicine, Duke University, Durham, NC, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gabi Kastenmüller
2Institute of Computational Biology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gabi Kastenmüller
Jan Krumsiek
3Institute for Computational Biomedicine, Englander Institute for Precision Medicine, Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jan Krumsiek
  • For correspondence: matthias.arnold{at}helmholtz-muenchen.de jak2043{at}med.cornell.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Preview PDF
Loading

Abstract

Impaired glucose uptake in the brain is one of the earliest presymptomatic manifestations of Alzheimer’s disease (AD). The absence of symptoms for extended periods of time suggests that compensatory metabolic mechanisms can provide resilience. Here, we introduce the concept of a systemic ‘bioenergetic capacity’ as the innate ability to maintain energy homeostasis under pathological conditions, potentially serving as such a compensatory mechanism. We argue that fasting blood acylcarnitine profiles provide an approximate peripheral measure for this capacity that mirrors bioenergetic dysregulation in the brain. Using unsupervised subgroup identification, we show that fasting serum acylcarnitine profiles of participants from the AD Neuroimaging Initiative yields bioenergetically distinct subgroups with significant differences in AD biomarker profiles and cognitive function. To assess the potential clinical relevance of this finding, we examined factors that may offer diagnostic and therapeutic opportunities. First, we identified a genotype affecting the bioenergetic capacity which was linked to succinylcarnitine metabolism and significantly modulated the rate of future cognitive decline. Second, a potentially modifiable influence of beta-oxidation efficiency seemed to decelerate bioenergetic aging and disease progression. Our findings, which are supported by data from more than 9,000 individuals, suggest that interventions tailored to enhance energetic health and to slow bioenergetic aging could mitigate the risk of symptomatic AD, especially in individuals with specific mitochondrial genotypes.

Competing Interest Statement

A.J.S is a member of the Scientific Advisory Board of Bayer Oncology and of the Dementia Advisory Board of Siemens Medical Solutions USA, Inc.; A.J.S received in kind support from Avid Radiopharmaceuticals, a subsidiary of Eli Lilly (PET tracer precursor); A.J.S. received Editorial Office Support as Editor-in-Chief from SPringer-Nature Publishing (Brain Imaging and Behavior). P.M.D. has received research grants (through Duke University) from Lilly, Avanir, Bausch, Alzheimer's Drug Discovery Foundation; P.M.D has received advisory fees from Verily, Otsuka, Genomind, Cogniciti, Clearview, VitaKey, Neuronix, Neuroglee, and Transposon Therapeutics; P.M.D owns shares or options in UMethod, Evidation Healthy, Transposon, Marvel Biome, and Advera Health; P.M.D serves on the board of Apollo and is a co-inventor (through Duke University) on patents relating to dementia biomarkers, metabolomics, and therapies. R.K.D holds equity in Metabolon Inc. M.A., R.K.D., and G.K. are co-inventors (through Duke University/Helmholtz Zentrum Muenchen) on patents on applications of metabolomics in disease of the central nervous system; M.A., R.K.D., G.K., and J.K. hold equity in Chymia LLC and IP in PsyProtix/atai Life Sciences N.V. that are exploring the potential for therapeutic applications targeting mitochondrial metabolism in treatment-resistant depression. J.K is confounder of iollo and advisor to Celeste Health and Strand Health.

Funding Statement

This work was supported by the National Institutes of Health/the National Institute of Aging through grants RF1AG058942, RF1AG059093, U01AG061359, U19AG063744 and R01AG069901. In addition, the following funding sources are acknowledged: ADNI: Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. Data collection and sharing for this project was further funded by the Alzheimer's Disease Metabolomics Consortium (National Institute on Aging R01AG046171, RF1AG051550 and 3U01AG024904-09S4). ROS/MAP: Study data were provided by the Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago. Data collection was supported through funding by NIA grants P30AG10161 (ROS), R01AG15819 (ROSMAP; genomics and RNAseq), R01AG17917 (MAP), R01AG30146, R01AG36042 (5hC methylation, ATACseq), RC2AG036547 (H3K9Ac), R01AG36836 (RNAseq), R01AG48015 (monocyte RNAseq) RF1AG57473 (single nucleus RNAseq), U01AG32984 (genomic and whole exome sequencing), U01AG46152 (ROSMAP AMP-AD, targeted proteomics), U01AG46161(TMT proteomics), U01AG61356 (whole genome sequencing, targeted proteomics, ROSMAP AMP-AD), the Illinois Department of Public Health (ROSMAP), and the Translational Genomics Research Institute (genomic). Additional phenotypic data can be requested at www.radc.rush.edu. MayoLOAD: Study data were provided by the Mayo Clinic Alzheimer's Disease Genetic Studies, led by Dr. Nilufer Ertekin-Taner and Dr. Steven G. Younkin, Mayo Clinic, Jacksonville, FL using samples from the Mayo Clinic Study of Aging, the Mayo Clinic Alzheimer's Disease Research Center, and the Mayo Clinic Brain Bank. Data collection was supported through funding by NIA grants P50 AG016574, R01 AG032990, U01 AG046139, R01 AG018023, U01 AG006576, U01 AG006786, R01 AG025711, R01 AG017216, R01 AG003949, NINDS grant R01 NS080820, CurePSP Foundation, and support from Mayo Foundation. KORA: The KORA study was initiated and financed by the Helmholtz Zentrum Muenchen - German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education and Research (BMBF) and by the State of Bavaria. AGES-RS: The AGES-RS study has been funded by NIH contract N01-AG-12100, the NIA Intramural Research Program, Hjartavernd (the Icelandic Heart Association) contract HHSN271201200022C, and the Althingi (the Icelandic Parliament). Funding sources had no role in study design, the collection, analysis and interpretation of data, the writing of the report, or in the decision to submit the article for publication.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

IRB of Duke University gave ethical approval for using ROS/MAP data (Pro00072976). IRB of Duke University waived ethical approval (determined exempt) for using ADNI-1/GO/2 data (Pro00053208) and AGES-RS data (Pro00093250). Data use agreements of KORA and MayoLOAD studies did not require separate IRB approval. MayoLOAD was approved by the appropriate IRB and appropriate informed consent was obtained from all participants. KORA, including the protocols for subject recruitment and assessment and the informed consent for participants, was reviewed and approved by the local ethical committee (Bayerische Landesaerztekammer).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted January 24, 2024.
Download PDF

Supplementary Material

Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Individual bioenergetic capacity as a potential source of resilience to Alzheimer’s disease
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Individual bioenergetic capacity as a potential source of resilience to Alzheimer’s disease
Matthias Arnold, Mustafa Buyukozkan, P. Murali Doraiswamy, Kwangsik Nho, Tong Wu, Vilmundur Gudnason, Lenore J. Launer, Rui Wang-Sattler, Jerzy Adamski, The Alzheimer’s Disease Neuroimaging Initiative, Alzheimer’s Disease Metabolomics Consortium, Philip L. De Jager, Nilüfer Ertekin-Taner, David A. Bennett, Andrew J. Saykin, Annette Peters, Karsten Suhre, Rima Kaddurah-Daouk, Gabi Kastenmüller, Jan Krumsiek
medRxiv 2024.01.23.23297820; doi: https://doi.org/10.1101/2024.01.23.23297820
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Individual bioenergetic capacity as a potential source of resilience to Alzheimer’s disease
Matthias Arnold, Mustafa Buyukozkan, P. Murali Doraiswamy, Kwangsik Nho, Tong Wu, Vilmundur Gudnason, Lenore J. Launer, Rui Wang-Sattler, Jerzy Adamski, The Alzheimer’s Disease Neuroimaging Initiative, Alzheimer’s Disease Metabolomics Consortium, Philip L. De Jager, Nilüfer Ertekin-Taner, David A. Bennett, Andrew J. Saykin, Annette Peters, Karsten Suhre, Rima Kaddurah-Daouk, Gabi Kastenmüller, Jan Krumsiek
medRxiv 2024.01.23.23297820; doi: https://doi.org/10.1101/2024.01.23.23297820

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Neurology
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)